News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
688,546 Results
Type
Article (39439)
Company Profile (306)
Press Release (648801)
Section
Business (204804)
Career Advice (2004)
Deals (35476)
Drug Delivery (87)
Drug Development (80999)
Employer Resources (168)
FDA (16118)
Job Trends (14861)
News (345838)
Policy (32548)
Tag
Academia (2548)
Alliances (49437)
Alzheimer's disease (1235)
Approvals (16049)
Artificial intelligence (130)
Bankruptcy (354)
Best Places to Work (11560)
Biotechnology (217)
Breast cancer (121)
Cancer (1089)
Cardiovascular disease (97)
Career advice (1672)
Cell therapy (236)
Clinical research (64377)
Collaboration (390)
Compensation (200)
COVID-19 (2547)
C-suite (95)
Data (1127)
Diabetes (153)
Diagnostics (6160)
Earnings (84950)
Employer resources (146)
Events (109997)
Executive appointments (310)
FDA (16659)
Funding (356)
Gene therapy (178)
GLP-1 (581)
Government (4339)
Healthcare (18690)
Infectious disease (2632)
Inflammatory bowel disease (110)
Interviews (308)
IPO (16337)
Job creations (3660)
Job search strategy (1429)
Layoffs (417)
Legal (7888)
Lung cancer (170)
Manufacturing (177)
Medical device (13187)
Medtech (13192)
Mergers & acquisitions (19218)
Metabolic disorders (404)
Neuroscience (1512)
NextGen Class of 2024 (6534)
Non-profit (4477)
Northern California (1484)
Obesity (232)
Opinion (183)
Patents (102)
People (56608)
Phase I (20013)
Phase II (28365)
Phase III (21133)
Pipeline (458)
Postmarket research (2555)
Preclinical (8525)
Radiopharmaceuticals (236)
Rare diseases (219)
Real estate (5936)
Regulatory (21591)
Research institute (2316)
Resumes & cover letters (350)
Southern California (1308)
Startups (3615)
United States (13549)
Vaccines (551)
Weight loss (169)
Date
Today (43)
Last 7 days (670)
Last 30 days (3678)
Last 365 days (35805)
2024 (32864)
2023 (40177)
2022 (51290)
2021 (55838)
2020 (54161)
2019 (46644)
2018 (35127)
2017 (32227)
2016 (31634)
2015 (37712)
2014 (31456)
2013 (26501)
2012 (28772)
2011 (29426)
2010 (27526)
Location
Africa (716)
Arizona (192)
Asia (37334)
Australia (6107)
California (3350)
Canada (1296)
China (253)
Colorado (148)
Connecticut (153)
Europe (80025)
Florida (461)
Georgia (116)
Illinois (344)
Indiana (197)
Kansas (97)
Maryland (576)
Massachusetts (2620)
Michigan (158)
Minnesota (273)
New Jersey (957)
New York (965)
North Carolina (703)
Northern California (1484)
Ohio (141)
Pennsylvania (849)
South America (1094)
Southern California (1308)
Texas (468)
Utah (90)
Washington State (363)
688,546 Results for "nielsen biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Nielsen Biosciences Announces Enrollment of First Patient in Phase 3 Trial of CANDIN for the Treatment of Common Warts
Nielsen BioSciences, Inc. today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN ® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.
March 5, 2024
·
3 min read
Business
Vial Partners with Nielsen BioSciences, Inc. in Phase III Clinical Trial for the Treatment of Common Warts
Vial, a global tech-driven CRO providing next-generation clinical trial management services, has partnered with Nielsen BioSciences, Inc. (Nielsen), a privately-held biopharmaceutical company based in San Diego, CA, to study the safety and efficacy of CANDIN® for the treatment of common warts.
June 14, 2023
·
5 min read
Business
Nielsen BioSciences, Inc. Enters into License Agreement with Maruho Co. Ltd. for the Treatment of Common Warts
Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced that it has entered into a license agreement with Maruho Co., Ltd. (“Maruho”), granting Maruho exclusive rights to market CANDINⓇ in Japan for the treatment of Verruca vulgaris (common warts).
May 16, 2023
·
5 min read
Press Releases
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
November 22, 2024
·
5 min read
Biotech Bay
Octave® Bioscience, Inc. Announces Publication in Nature Communications
Octave ® Bioscience, Inc. today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.
May 29, 2024
·
5 min read
Press Releases
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
November 13, 2024
·
6 min read
Press Releases
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
November 12, 2024
·
4 min read
Press Releases
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
November 14, 2024
·
8 min read
Business
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
Co-Diagnostics, Inc. today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO).
April 4, 2024
·
5 min read
Business
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Xenetic Biosciences, Inc. today announced the appointment of James Parslow, the Company’s Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024.
May 22, 2024
·
5 min read
1 of 68,855
Next